Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Androgen receptor (AR) signaling drives prostate cancer (PCa) growth.
• Androgen deprivation therapy (ADT) is a primary treatment for hormone-sensitive PCa (HSPC).
• Resistance to ADT leads to castration-resistant prostate cancer (CRPC), often due to sustained AR signaling.

Purpose of the Study:

• To review the interplay between AR signaling and other molecular pathways in PCa.
• To discuss mechanisms of resistance to ADT in advanced prostate cancer.
• To highlight therapeutic implications for advanced PCa.

Main Methods:

• Literature review of recent advancements in prostate cancer management.
• Analysis of molecular pathways involved in PCa pathogenesis.
• Discussion of therapeutic strategies targeting AR signaling and alternative pathways.

Main Results:

• AR signaling is central to PCa, but alternative pathways are crucial for progression.
• Mechanisms of resistance to ADT involve sustained AR signaling and activation of other pathways.
• Multiple pathways, including DNA damage response, PI3K/AKT/mTOR, and immune response, are implicated in CRPC.

Conclusions:

• Understanding the crosstalk between AR and other pathways is vital for treating advanced PCa.
• Targeting AR signaling in combination with other pathways may overcome treatment resistance.
• Further research into these interactions can lead to novel therapeutic approaches for CRPC.